WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written informed consent.

Trial Details

NCT ID
NCT04644289
Phase
PHASE2
Sponsor
AGO Research GmbH
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • olaparib
  • durvalumab
Locations (sample)
  • Mannheim, Baden-Wurttemberg, Germany|49.4891,8.46694
  • München, Bavaria, Germany|48.69668,13.46314
  • Essen, North Rine-Westphalia, Germany|51.45657,7.01228
  • Dresden, Saxony, Germany|51.05089,13.73832
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • WoO pre-treatment (screening phase):
  • Patients with presumed and previously untreated advanced stage ovarian cancer planned to undergo laparoscopy for histologic diagnosis and treatment…
  • Patients willing and able to comply with the study protocol for the duration of the study including undergoing treatment and scheduled visits and e…
  • Patients able and willing to provide fresh frozen biopsy samples from laparoscopy as well as primary debulking for translational endpoints as well …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →